Brief DBT Skills Training for Coping With Suicidal Ideation

September 2, 2025 updated by: Muhammed Ali Boztepe

Brief Dialectical Behavior Therapy-Skills Training for Coping With Suicidal Ideation: A Randomized Controlled Trial

The goal of this clinical trial is to learn if Brief Dialectical Behavior Therapy Skills Training (DBT-BST) can prevent suicidality in adults. The main questions it aims to answer are:

  • Does DBT-BST provide coping strategies (e.g., emotion regulation) to participants with suicidal ideation?
  • Does DBT-BST lower participants' suicide ideation?

Researchers will compare DBT-BST to relaxation to see if DBT-BST works to reduce suicidal ideation.

Participants will:

  • Receive DBT-BST in a single 60-minute, in-person, individual session.
  • Be asked to use these skills as self-help and for crisis prevention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
    • Aydın
      • Aydin, Aydın, Turkey (Türkiye), 09500
        • Aydın Adnan Menderes University, Suicide and Stress Research Laboratory

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • being 18 years of age or older
  • having suicidal ideation in the last 3 months
  • not having received any psychological treatment in the last 1 month
  • living in Aydın/Türkiye where the intervention will be implemented
  • giving consent for participation

Exclusion Criteria:

  • not speaking Turkish
  • loss or trauma in the last 1 year
  • pharmacological treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Brief Dialectical Behavior Therapy-Skills Training
Behavioral: Brief Dialectical Behavior Therapy-Skills Training

The intervention is administered in a single session, lasting approximately 60 minutes and conducted in person. It is important to note that there are no ongoing sessions.

In the intervention, participants are provided with 5 basic skills of Dialectical Behavior Therapy: 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing body chemistry. These strategies are grouped under 3 categories: 1) Mindfulness, 2) Emotion regulation (mindfulness of current emotions, opposite-to-emotion action), 3) Tolerating distress (distraction, changing body chemistry). These skills are not designed to treat or solve the crisis. The main aim is to provide effective coping mechanisms that can be implemented quickly before the crisis escelates, to help overcome the intense emotional pain and keep the person alive.
Active Comparator: Relaxation control group
Behavioral: Relaxation
The control group will be subjected to a relaxation exercise, with the objective of managing participant expectations, researcher attention/interest, and time spent, as well as providing a coping strategy for stress.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in the Suicidality at 1 Month as Assessed by Suicide Probability Scale
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
36 is equivalent to the lowest suicidality, and 144 indicates the highest suicidality.
From enrollment to the end of intervention at 1 week and follow-up at 1 month
Change from Baseline in the Suicidal Cognitions at 1 Month as Assessed by Suicide Cognitions Scale
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
18 is equivalent to the lowest suicidal cognitions, and 90 indicates the highest suicidal cognitions.
From enrollment to the end of intervention at 1 week and follow-up at 1 month
Change from Baseline in the Hopelessness at 1 Month as Assessed by Beck Hopelessness Scale
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
Zero is equivalent to the lowest hopelessness, and 20 indicates the highest hopelessness.
From enrollment to the end of intervention at 1 week and follow-up at 1 month
Change from Baseline in the Emotion Regulation Skills at 1 Month as Assessed by Emotion Regulation Skills Questionnaire
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
Zero is equivalent to the lowest emotion regulation skills, and 108 indicates the highest skills.
From enrollment to the end of intervention at 1 week and follow-up at 1 month
Change from Baseline in the Difficulties in Emotion Regulation at 1 Month as Assessed by Difficulties in Emotion Regulation Scale-16
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
16 is equivalent to the lowest difficulties, and 80 indicates the highest difficulties in emotion regulation.
From enrollment to the end of intervention at 1 week and follow-up at 1 month

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in the Depression, Anxiety, and Stress at 1 Month as Assessed by Depression Anxiety Stress Scale-21 (DASS-21)
Time Frame: From enrollment to the end of intervention at 1 week and follow-up at 1 month
Higher points are equivalent to higher symptoms as assessed by the related subscale of DASS-21. Each subscale ranges from 0 to 28.
From enrollment to the end of intervention at 1 week and follow-up at 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Muhammed Ali Boztepe

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 18, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 18, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 26, 2025

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 8, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 2, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BriefDBT-ST30/05/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings